170 related articles for article (PubMed ID: 17414113)
1. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma.
Blokx WA; Lesterhuis WJ; Andriessen MP; Verdijk MA; Punt CJ; Ligtenberg MJ
Am J Surg Pathol; 2007 Apr; 31(4):637-41. PubMed ID: 17414113
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
5. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.
Küsters-Vandevelde HV; Keunen JE; Wesseling P; Verdijk MA; Ligtenberg MJ; Blokx WA
Virchows Arch; 2008 Mar; 452(3):331-6. PubMed ID: 18205010
[TBL] [Abstract][Full Text] [Related]
7. Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation.
Edinger JT; Radfar A; Jukic DM
J Cutan Pathol; 2009 Oct; 36 Suppl 1():74-9. PubMed ID: 19281486
[TBL] [Abstract][Full Text] [Related]
8. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
9. Morphologic diversity in malignant melanoma: the potential use of microdissection and the polymerase chain reaction for diagnosis.
Quezado MM; Abati AD; Albuquerque AV; Wilson J; Merino MJ; Filie AC
Mod Pathol; 1998 Oct; 11(10):1010-5. PubMed ID: 9796732
[TBL] [Abstract][Full Text] [Related]
10. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
12. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
[TBL] [Abstract][Full Text] [Related]
13. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma.
Pedace L; De Simone P; Castori M; Sperduti I; Silipo V; Eibenschutz L; De Bernardo C; Buccini P; Moscarella E; Panetta C; Ferrari A; Grammatico P; Catricalà C
Cancer Epidemiol; 2011 Dec; 35(6):e116-20. PubMed ID: 21893440
[TBL] [Abstract][Full Text] [Related]
14. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
[TBL] [Abstract][Full Text] [Related]
15. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
[TBL] [Abstract][Full Text] [Related]
16. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
18. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.
Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA
Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365
[TBL] [Abstract][Full Text] [Related]
19. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
20. The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil.
Bakos RM; Besch R; Zoratto GG; Godinho JM; Mazzotti NG; Ruzicka T; Bakos L; Santos SE; Ashton-Prolla P; Berking C; Giugliani R
Exp Dermatol; 2011 Nov; 20(11):890-3. PubMed ID: 21895773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
